title: PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Steffan
authors.initials: S
authors.lastname: Crausaz
authors.forename: Peter
authors.initials: P
authors.lastname: Moodie
authors.forename: Wayne
authors.initials: W
authors.lastname: McNee
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000191:economics* / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D017277:Drug Approval / Q000191:economics*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D009313:National Health Programs / Q000191:economics; D009520:New Zealand; D012945:Social Values; D000077204:Temozolomide; D013727:Terminal Care / Q000191:economics / Q000941:ethics
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide